Pembrolizumab trials for Triple Negative Breast Cancer (TNBC)

All Pembrolizumab trials · All Triple Negative Breast Cancer (TNBC) trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Triple Negative Breast Cancer (TNBC)

• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
  NCT07743190 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
  NCT06606730 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
  NCT07652242 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 2 locations
• Study of XB010 in Subjects With Solid Tumors
  NCT06545331 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations

Common questions

How many trials study Pembrolizumab for Triple Negative Breast Cancer (TNBC)?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.